• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » i3, Acurian in Patient Recruitment Deal

i3, Acurian in Patient Recruitment Deal

December 1, 2009
CenterWatch Staff

Pharmaceutical services company i3 has entered into an agreement with Acurian, a provider of patient recruitment and retention solutions, to provide study sponsors with a more robust solution to recruit investigators for clinical trials. 

Acurian’s patient database will be complemented by new i3 services that offer statistics for improved planning and identification of trial sites with greater access to appropriate patient populations.

With its proprietary access to a large database of information relating to private insurance claims, i3 can identify potential investigators throughout the United States and rank them according to the number of patients available who match the required study-specific criteria.

The effectiveness of this informatics capability was confirmed in a study that i3 published earlier this year that demonstrated that the top-ranking investigators enroll patients twice as fast. 

With 70% of all clinical trials missing their timelines, according to an industry survey, the application of i3’s clinical informatics can make an appreciable difference in meeting customers’ enrollment goals. Patients visit Acurian.com and affiliated sources to sign up voluntarily for information about upcoming clinical trials of interest. 

This direct-to-patient approach has netted Acurian a database of more 50 million patients who have self-reported a wide variety of ailments and want to receive healthcare information, including clinical trial opportunities in their local area.

“Pairing i3's clinical informatics solutions with Acurian’s patient assets will offer a unique product to the marketplace and articularly benefit sponsors of studies anticipating or experiencing enrollment issues,” said Tom Abbott, president of i3 Pharma Informatics. “It also represents an additional opportunity to increase i3’s brand penetration among pharmaceutical, biotech, and medical device sponsors.”

Bill Gwinn, vice president of Clinical Informatics at i3 Pharma Informatics, added, “This agreement will further cement our reputation as a clinical research organization on which sponsors rely to execute difficult trials. 78,000 investigators in i3’s U.S. database, combined with more than 50 million patients in Acurian’s database, will yield a comprehensive view of sites, investigators, and patients to help our customers achieve their enrollment targets.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing